natgillin/translations-raw huggingface dataset:
The adverse reactions considered at least possibly related to treatment with the components of Triumeq from clinical study and post-marketing experience are listed in Table 2 by body system, organ class and absolute frequency. 
Tablični prikaz nuspojava Nuspojave prijavljene u kliničkim ispitivanjima i nakon stavljanja lijeka u promet, čija se povezanost sa sastavnicama lijeka Triumeq smatra barem mogućom, navedene su u Tablici 2 prema klasifikaciji organskih sustava i apsolutnoj učestalosti.
Abacavir is primarily metabolised by the liver with approximately 2% of the administered dose being renally excreted, as unchanged compound. 
Abakavir se primarno metabolizira u jetri, a približno 2% primijenjene doze izlučuje se kroz bubrege u nepromijenjenu obliku.
Lamivudine monotherapy is generally not considered an adequate treatment for hepatitis B, since the risk for hepatitis B resistance development is high. 
Zbog visokog rizika od razvoja rezistencije hepatitisa B, monoterapija lamivudinom obično se ne smatra prikladnim liječenjem za hepatitis B.
- Restarting abacavir containing products following a suspected abacavir HSR can result in a prompt return of symptoms within hours. 
- Ponovno uvođenje lijekova koji sadrže abakavir nakon suspektne reakcije preosjetljivosti na abakavir može dovesti do brzog povratka simptoma unutar svega nekoliko sati.
Increases in serum creatinine occurred within the first week of treatment with dolutegravir and remained stable through 96 weeks. 
Povećanja koncentracije kreatinina u serumu nastupila su u prvome tjednu liječenja dolutegravirom,
Virologic suppression (HIV-1 RNA <50 copies/mL) in the ABC/DTG/3TC FDC group (85%) was statistically non-inferior to the current ART groups (88%) at 24 weeks. 
Virusna supresija (HIV-1 RNK < 50 kopija/ml) u 24. tjednu u skupini koja je primala fiksnu kombinaciju ABC/DTG/3TC (85%) bila je neinferiorna onoj u skupinama koje su nastavile primati dotadašnju antiretrovirusnu terapiju (88%).
ABC HSR educational material for health care professionals 
• Edukacijske materijale o reakcijama preosjetljivosti na abakavir za zdravstvene radnike
There is no evidence that a dose adjustment of dolutegravir, abacavir or lamivudine would be required based on the effects of gender on PK parameters. 
Nema dokaza da bi bilo potrebno prilagoditi dozu dolutegravira, abakavira ili lamivudina na temelju učinaka spola na farmakokinetičke parametre.
In vitro, dolutegravir inhibited the renal transporters OCT2 and MATE1. 
Dolutegravir je in vitro inhibirao bubrežne prijenosnike OCT2 i MATE1.
No Triumeq dosage adjustment necessary, unless patient has renal impairment (See Section 4.2). 
Triumeq, osim ako bolesnik nema oštećenje bubrežne funkcije (vidjeti dio 4.2).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING BOTTLE CARTON (INDIVIDUAL PACKS ONLY) 
KUTIJA ZA BOCU (SAMO POJEDINAČNA PAKIRANJA)
Each pack of 30 film-coated tablets contains a desiccant. 
Jedno pakiranje s 30 filmom obloženih tableta sadrži sredstvo za sušenje.
• difficulty in sleeping (insomnia) 
• tegobe sa spavanjem (nesanica) • nedostatak energije (umor)
Virologic non response† No virologic data at Weeks 48 window Reasons Discontinued study/study drug due to adverse event or death‡ Discontinued study/study drug for other reasons§ Missing data during window but on study HIV-1 RNA <50copies/mL for those on ABC/3TC Median time to viral suppression** 
Izostanak virološkog odgovora† Nema viroloških podataka unutar 48 tjedana Razlozi Prekid sudjelovanja u ispitivanju/primjene ispitivanog lijeka zbog nuspojave ili smrti‡ Prekid sudjelovanja u ispitivanju/primjene ispitivanog lijeka zbog drugih razloga§ HIV-1 RNK < 50 kopija/ml u bolesnika koji primaju ABC/3TC
In SPRING-2, 822 patients were treated with either dolutegravir 50 mg once daily or raltegravir 400 mg twice daily (blinded), both with fixed-dose ABC/3TC (around 40%) or TDF/FTC (around 60%), given open label. 
U ispitivanju SPRING-2, 822 bolesnika liječena su ili dolutegravirom u dozi od 50 mg jedanput na dan ili raltegravirom u dozi od 400 mg dvaput na dan (slijepo liječenje); oba su se lijeka primjenjivala u kombinaciji s fiksnom dozom ABC/3TC (približno 40%) ili TDF/FTC (približno 60%), koja se davala otvoreno.
vomiting, flatulence, abdominal pain, abdominal pain upper, abdominal distension, abdominal discomfort, gastrooesophageal reflux disease, dyspepsia 
povraćanje, flatulencija, bol u abdomenu, bol u gornjem dijelu abdomena, distenzija abdomena, nelagoda u abdomenu, gastroezofagealna refluksna bolest, dispepsija rijetko:
HIV-1 RNA <50 copies/mL Treatment Difference* 
HIV-1 RNK <50 kopija/ml
Since the recommended dose of dolutegravir is 50 mg twice daily for patients with resistance to integrase inhibitors, the use of Triumeq is not recommended for patients with integrase inhibitor resistance. 
Budući da preporučena doza dolutegravira za bolesnike s rezistencijom na inhibitore integraze iznosi 50 mg dvaput na dan, primjena lijeka Triumeq ne preporučuje se u bolesnika s rezistencijom na inhibitore integraze.
You must carefully read all the information under ‘Hypersensitivity reactions' in the panel in Section 4. 
Morate pažljivo pročitati sve informacije u odlomku 'Reakcije preosjetljivosti' u dijelu 4.
In vitro, dolutegravir inhibited the renal uptake organic anion transporters (OAT)1 and OAT3. 
In vitro je dolutegravir inhibirao bubrežne prijenosnike za unos organskih aniona OAT1 i OAT3.
The symptoms related to this HSR worsen with continued therapy and can be lifethreatening. 
Simptomi povezani s tom reakcijom preosjetljivosti pogoršavaju se s nastavkom terapije i mogu ugroziti život.
R263K was reported from two individual patients with subtype B and subtype C in the clinical program for ART experienced, INI naive subjects, but without effects on dolutegravir susceptibility in vitro. 
kliničkom je programu mutacija R263K prijavljena u dva bolesnika s podvrstom B i podvrstom C koji su prethodno primali antiretrovirotike, ali ne i inhibitore integraze, no ona nije utjecala na osjetljivost na dolutegravir in vitro.
PHARMACEUTICAL FORM AND CONTENTS Multipack: 90 (3 packs of 30) film-coated tablets 
Višestruko pakiranje: 90 (3 pakiranja s 30) filmom obloženih tableta
In rabbits, maternal toxicity (decreased food consumption, scant/no faeces/urine, suppressed body weight gain) was observed at 1000 mg/kg (0.74 times the 50 mg human clinical exposure when administered in combination with abacavir and lamivudine based on AUC). 
U kunića je toksičnost za majku (smanjen unos hrane, slabo izlučivanje/izostanak izlučivanja fecesa/mokraće, suprimiran prirast tjelesne težine) primijećena pri primjeni doze od 1000 mg/kg (izloženost 0,74 puta veća od kliničke izloženosti u ljudi pri primjeni doze od 50 mg u kombinaciji s abakavirom i lamivudinom, što je utvrđeno na temelju
Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, Pglycoprotein (P-gp), and breast cancer resistance protein (BCRP). 
Dolutegravir se uglavnom eliminira metabolizmom u kojem posreduje uridindifosfat glukuronoziltransferaza (UGT) 1A1. Dolutegravir je i supstrat za UGT1A3, UGT1A9, CYP3A4, P-glikoprotein (P-gp) te protein rezistencije raka dojke (engl. breast cancer resistance protein, BCRP).
Dolutegravir ↓ (Not studied, a similar reduction in exposure as observed with efavirenz is expected, due to induction) 
nevirapin/dolutegravir dolutegravir ↓ (nije ispitivano, zbog indukcije se očekuje smanjenje izloženosti slično onome kod primjene efavirenza)
Abacavir is primarily metabolised by the liver with approximately 2% of abacavir excreted unchanged in the urine. 
Abakavir se prvenstveno metabolizira u jetri, a približno 2% abakavira izlučuje se kroz mokraću u nepromijenjenu obliku.
• rifampicin, to treat tuberculosis (TB) and other bacterial infections 
• kladribin, koji se koristi za liječenje leukemije vlasastih stanica • rifampicin, koji se koristi za liječenje tuberkuloze (TBC) i drugih bakterijskih infekcija
In vitro, abacavir did not inhibit or induce CYP enzymes (such as CYP3A4, CYP2C9 or CYP2D6) and demonstrates no or weak inhibition of OATP1B1, OAT1B3, OCT1, OCT2, BCRP and P-gp or 
In vitro, abakavir nije inhibirao ni inducirao CYP enzime (kao što su CYP3A4, CYP2C9 ili CYP2D6) te nije inhibirao ili je slabo inhibirao OATP1B1, OAT1B3, OCT1, OCT2, BCRP i P-gp ili MATE2-K.
Abacavir is metabolised by UGT (UGT2B7) and alcohol dehydrogenase; co-administration of inducers (e.g. rifampicin, carbamazepine and phenytoin) or inhibitors (e.g. valproic acid) of UGT enzymes or with compounds eliminated through alcohol dehydrogenase could alter abacavir exposure. 
Abakavir se metabolizira posredstvom UGT-a (UGT2B7) i alkohol-dehidrogenaze; istodobna primjena induktora (npr. rifampicina, karbamazepina i fenitoina) ili inhibitora (npr. valproatne kiseline)
In HIV-infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. 
U bolesnika s HIV infekcijom i teškom imunodeficijencijom u trenutku uvođenja kombinirane antiretrovirusne terapije može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
Lamivudine is also substrate of the hepatic uptake transporter OCT1. 
Lamivudin je i supstrat prijenosnika za unos tvari u jetru OCT1.
Triumeq should not be used in patients who are known to carry the HLA-B*5701 gene. 
Triumeq ne smiju uzimati bolesnici za koje se zna da su nositelji gena HLA-B*5701.
Mitochondrial dysfunction Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage. 
Pokazalo se da nukleozidni i nukleotidni analozi uzrokuju različite stupnjeve mitohondrijskog oštećenja in vitro i in vivo.
• St. John's wort (Hypericum perforatum), a herbal remedy to treat depression 
• gospinu travu (Hypericum perforatum), biljni lijek za liječenje depresije • metadon, koji se koristi kao nadomjesna terapija za heroin.
Similar IC50s were seen for clinical isolates without any major difference between subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC50 value was 0.2 nM (range 0.02-2.14). 
viđene su i kod kliničkih izolata, bez većih razlika među podvrstama; na paleti od 24 izolata HIV-1 iz linija A, B, C, D, E, F i G te skupine
The pharmacokinetic properties of dolutegravir, lamivudine and abacavir are described below. 
Farmakokinetičke značajke dolutegravira, lamivudina i abakavira opisane su u nastavku.
Uncommon side effects that may show up in blood tests are: 
Rijetke nuspojave koje se mogu vidjeti u nalazima krvnih pretraga:
Table 6: Demographics and Week 48 virologic outcomes of randomized treatment of ARIA (snapshot algorithm) 
Tablica 6: Demografske značajke i virološki ishodi u 48. tjednu randomiziranog liječenja u ispitivanju ARIA (snapshot algoritam)
Dolutegravir ↔ (Not studied) 
nelfinavir/dolutegravir dolutegravir ↔ (nije ispitivano)
Late Switch ABC/DTG/3TC FDC N=244 n (%) 
Kasni prelazak na fiksnu kombinaciju ABC/DTG/3TC N=244 n (%)
Hypersensitivity case studies 
Prikaz slučajeva preosjetljivosti
DTG 50 mg once daily + 2 NRTI N=411 
DTG 50 mg jedanput na dan + 2 NRTI N=411
No specific symptoms or signs have been identified following acute overdose with dolutegravir, abacavir or lamivudine, apart from those listed as adverse reactions. 
Nakon akutnog predoziranja dolutegravirom, abakavirom ili lamivudinom nisu primijećeni nikakvi posebni simptomi ni znakovi, osim onih koji su navedeni kao nuspojave.
• Shortness of breath, sore throat or cough 
• nedostatak zraka, grlobolja ili kašalj
Rarely, patients who have stopped abacavir for reasons other than symptoms of HSR have also experienced life-threatening reactions within hours of re- initiating abacavir therapy (see Section 4.8 Description of selected adverse reactions). 
U rijetkim su slučajevima po život opasne reakcije zabilježene unutar svega nekoliko sati nakon ponovnog uvođenja abakavira u bolesnika koji su liječenje abakavirom prekinuli zbog drugih razloga, a ne zbog simptoma reakcija preosjetljivosti (vidjeti dio 4.8, Opis odabranih nuspojava).
General disorders and administration site conditions: Very common: 
Opći poremećaji i reakcije na mjestu primjene: vrlo često:
• stomach (abdominal) pain 
• nelagoda u trbuhu (abdomenu)
IMPORTANT - Hypersensitivity reactions 
Upozorenja i mjere opreza VAŽNO - Reakcije preosjetljivosti
Hypersensitivity reactions have been observed more commonly with abacavir, some of which have been life-threatening, and in rare cases fatal, when not managed appropriately. 
Neke od njih bile su opasne po život, a u rijetkim su slučajevima imale i smrtni ishod ako nisu bile adekvatno zbrinute.
Do not take supplements or multivitamins containing calcium, iron or magnesium during the 6 hours before you take Triumeq, or for at least 2 hours after you take it. 
Ne smijete uzeti nadomjeske ili multivitaminske pripravke koji sadrže kalcij, željezo ili magnezij unutar 6 sati prije primjene lijeka Triumeq niti još najmanje 2 sata nakon njegove primjene.
Lamivudine is predominately cleared by renal excretion of unchanged lamivudine. 
Lamivudin se najvećim dijelom uklanja izlučivanjem putem bubrega u nepromijenjenu obliku.
M184V mutants display greatly reduced susceptibility to lamivudine and show diminished viral replicative capacity in vitro. 
pokazuju uvelike smanjenu osjetljivost na lamivudin i smanjenu sposobnost virusne replikacije in vitro.
Dolutegravir ↓ AUC ↓ 54% Cmax ↓ 43% Cτ ↓ 72% (induction of UGT1A1 and CYP3A enzymes) 
Antimikobakterijski lijekovi rifampicin/dolutegravir dolutegravir ↓ AUC ↓ 54% Cmax ↓ 43% Cτ ↓ 72% (indukcija enzima UGT1A1 i CYP3A)
Co-administration of Triumeq and other medicinal products that inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may therefore increase dolutegravir plasma concentration. 
UGT1A9, CYP3A4 i/ili P-gp stoga može povećati koncentracije dolutegravira u plazmi.
Population pharmacokinetic analysis of dolutegravir using data in HIV-1 infected adults showed that there was no clinically relevant effect of age on dolutegravir exposure. 
Populacijska farmakokinetička analiza dolutegravira na temelju podataka prikupljenih u odraslih osoba s HIV-1 infekcijom pokazala je da dob nije imala klinički značajan učinak na izloženost dolutegraviru.
Supplements or multivitamins containing calcium, iron or magnesium should be taken well separated in time from the administration of Triumeq (minimum 2 hours after or 6 hours before). 
Nadomjeske ili multivitaminske pripravke koji sadrže kalcij, željezo ili magnezij treba uzimati s većim vremenskim odmakom u odnosu na primjenu lijeka Triumeq (najmanje 2 sata nakon ili 6 sati prije).
• breakdown of muscle tissue 
• upala gušterače (pankreatitis) • razgradnja mišićnog tkiva
Do not take supplements or multivitamins containing calcium, iron or magnesium during the 6 hours before you take Triumeq, or for at least 2 hours after you take it (see also Section 3). 
Ne smijete uzeti nadomjeske ili multivitaminske pripravke koji sadrže kalcij, željezo ili magnezij unutar 6 sati prije primjene lijeka Triumeq niti još najmanje 2 sata nakon njegove primjene (pogledajte i dio 3.)
Abacavir has a weak potential to cause chromosomal damage both in vitro and in vivo at high tested concentrations. 
Ispitivanja su pokazala da visoke koncentracije abakavira imaju slab potencijal da izazovu kromosomska oštećenja in vitro i in vivo.
Antiviral activity in combination with other antiviral agents No antagonistic effects in vitro were seen with dolutegravir and other antiretrovirals (tested agents: stavudine, abacavir, efavirenz, nevirapine, lopinavir, amprenavir, enfuvirtide, maraviroc, adefovir and raltegravir). 
Nisu primijećeni antagonistički učinci in vitro kod primjene dolutegravira i drugih antivirotika (ispitivani lijekovi: stavudin, abakavir, efavirenz, nevirapin, lopinavir, amprenavir, enfuvirtid,
Dolutegravir ↓ AUC ↓ 39% Cmax ↓ 37% C24 ↓ 39% (Complex binding to polyvalent ions) 
nadomjesci kalcija/dolutegravir dolutegravir ↓ AUC ↓ 39% Cmax ↓ 37% C24 ↓ 39% (stvaranje kompleksa s polivalentnim ionima)
13.4 g)/Lamivudine oral solution 300 mg Lamivudine: 
Jednokratna doza oralne otopine lamivudina od 300 mg lamivudin:
Nevirapine/Dolutegravir 
lamivudin i dolutegravir.
Moderate amount of data (more than 600 outcomes from first trimester) indicates no malformative toxicity for abacavir. 
Umjerena količina podataka o primjeni abakavira (više od 600 ishoda nakon izloženosti u prvom tromjesečju trudnoće) ne ukazuje na malformacijsku toksičnost.
• indigestion 
• omamljenost
Similar levels of virologic suppression were maintained in both the Early and Late Switch groups at 48 weeks. 
Virusna supresija u 48. tjednu održala se na sličnoj razini i u skupini koja je rano prešla na fiksnu kombinaciju i u onoj koja prešla kasnije.
HIV-1 RNA <50 copies/mL for those on ABC/3TC * Adjusted for baseline stratification factors. 
HIV-1 RNK <50 kopija/ml u bolesnika koji primaju ABC/3TC Medijan vremena do virusne supresije**
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in more than 
• rasprostranjen osip praćen mjehurićima i ljuštenjem kože, osobito oko usta, nosa, očiju i genitalija
In ARIA (ING117172), a randomized, open-label, active-controlled, multicenter, parallel group, noninferiority study; 499 HIV-1 infected ART naïve adult women were randomized 1:1 to receive either; DTG/ABC/3TC FDC 50 mg/600 mg/300 mg; or atazanavir 300 mg plus ritonavir 100 mg plus tenofovir disproxil / emtricitabine 245 mg/200 mg (ATV+RTV+TDF/FTC FDC), all administered once daily. 
HIV-1 infekcijom koje prethodno nisu primale antiretrovirusnu terapiju bilo je randomizirano u omjeru 1:1 za primanje fiksne kombinacije DTG/ABC/3TC u dozi od 50 mg/600 mg/300 mg ili za primanje atazanavira u dozi od 300 mg plus ritonavira u dozi od 100 mg plus fiksne kombinacije tenofovirdizoproksila/emtricitabina u dozi od 245 mg/200 mg (ATV+RTV+ fiksna kombinacija TDF/FTC); svi ti lijekovi primjenjivali su se jedanput na dan.
Demographics Median Age (years) Female Non-white Hepatitis B and/ or C CDC class C Week 48 Efficacy Results HIV-1 RNA <50 copies/mL Treatment difference 
Demografske značajke medijan dobi (godine) žene ispitanici koji nisu bijelci hepatitis B i/ili C kategorija C prema CDC klasifikaciji osnovno liječenje kombinacijom ABC/3TC
Dolutegravir, abacavir and lamivudine have been shown to inhibit replication of lab-strains and clinical isolates of HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and primary cultures of activated peripheral blood mononuclear cells (PMBCs) and monocyte/macrophages. 
T-limfocita, stanične linije nastale od monocita/makrofaga te primarne kulture aktiviranih mononuklearnih stanica periferne krvi i monocita/makrofaga.
Table 4: Demographics and virologic outcomes of randomized treatment of SPRING-2 (snapshot algorithm) 
Tablica 4: Demografske značajke i virološki ishodi randomiziranog liječenja u ispitivanju SPRING-2
Following a single dose of 600 mg of abacavir, the mean (CV) Cmax is 4.26 µg/ml (28%) and the mean (CV) 
Nakon jednokratne doze abakavira od 600 mg, srednja vrijednost (CV) Cmax iznosi 4,26 µg/ml (28%), a srednja vrijednost (CV) AUC∞ 11,95 µg.h/ml (21%).
NAME OF THE MEDICINAL PRODUCT Triumeq 50 mg/600 mg/300 mg film-coated tablets 
Triumeq 50 mg/600 mg/300 mg filmom obložene tablete
Mild myocardial degeneration in the heart of mice and rats was observed following administration of abacavir for two years. 
Nakon dvogodišnje primjene abakavira primijećena je blaga degeneracija miokarda u srcima miševa i štakora.
MARKETING AUTHORISATION NUMBER(S) EU/1/14/940/002 
EU/1/14/940/001 EU/1/14/940/002
Iron supplements/Dolutegravir Dolutegravir ↓ AUC ↓ 54% Cmax ↓ 57% C24 ↓ 56% (Complex binding to polyvalent ions) 
nadomjesci željeza/dolutegravir dolutegravir ↓ AUC ↓ 54% Cmax ↓ 57% C24 ↓ 56% (stvaranje kompleksa s polivalentnim ionima)
dizziness, somnolence, lethargy1 
omaglica, somnolencija, letargija1
Non-white 
Rasa bijelci
DTG/ABC/3TC FDC N=248 
Fiksna kombinacija DTG/ABC/3TC N=248
The risk for abacavir HSR to occur is high for patients who test positive for the HLA-B*5701 allele. 
Rizik od pojave reakcija preosjetljivosti na abakavir je visok u bolesnika s pozitivnim nalazom na alel HLA-B*5701.
Other common symptoms are: nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness. 
Drugi česti simptomi su: mučnina, povraćanje, proljev, bol u trbuhu, izrazit umor.
Triumeq includes lamivudine, which is active against hepatitis B. Abacavir and dolutegravir lack such activity. 
Triumeq sadrži lamivudin, koji djeluje protiv hepatitisa B.
Dolutegravir is highly bound (> 99%) to human plasma proteins based on in vitro data. 
Podaci in vitro pokazuju da se dolutegravir u visokom stupnju (> 99%) veže za proteine u plazmi ljudi.
The IC50 for dolutegravir in various lab-strains using PBMC was 0.5 nM, and when using MT-4 cells it ranged from 0.7-2 nM. 
IC50 za dolutegravir u različitim laboratorijskim sojevima na mononuklearnim stanicama periferne krvi iznosio je 0,5 nM, a na MT-4 stanicama kretao se u rasponu od 0,7-2 nM. Slične vrijednosti IC50
The clinical status of the patient and the adverse reaction profile of Triumeq should be borne in mind when considering the patient's ability to drive or operate machinery. 
Kada se razmatra bolesnikova sposobnost upravljanja vozilima ili rada sa strojevima, na umu treba imati kliničko stanje bolesnika i profil nuspojava lijeka Triumeq.
Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with etravirine (without boosted protease inhibitors), efavirenz, nevirapine, rifampicin, tipranavir/ritonavir, carbamazepine, phenytoin, phenobarbital and St. John's wort, the use of Triumeq is not recommended for patients taking these medicines (see section 4.5). 
Budući da pri istodobnoj primjeni s etravirinom (bez pojačanih inhibitora proteaze), efavirenzom, nevirapinom, rifampicinom, tipranavirom/ritonavirom, karbamazepinom, fenitoinom, fenobarbitalom i gospinom travom, preporučena doza dolutegravira iznosi 50 mg dvaput na dan, primjena lijeka
Abacavir should not be used in patients known to carry the HLA-B*5701 allele. 
Abakavir se ne smije primjenjivati u bolesnika za koje se zna da su nositelji alela HLA-B*5701.
Reproductive toxicology 
Antiretrovirusni lijekovi
These may affect up to 1 in 1000 people: 
Rijetke nuspojave Mogu se javiti u do 1 na 1000 osoba:
AUC ↓ 32% 
abakavir AUC ↓ 32%
Population PK analyses using pooled pharmacokinetic data from Phase IIb and Phase III adult trials revealed no clinically relevant effect of race on the exposure of dolutegravir. 
Populacijska farmakokinetička analiza objedinjenih farmakokinetičkih podataka iz ispitivanja faze IIb i faze III u odraslih bolesnika nije ukazala na klinički značajan učinak rase na izloženost dolutegraviru.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4). 
međutim, prijavljeno vrijeme do njihova nastupa je različito pa se ti događaji mogu javiti i mjesecima nakon uvođenja liječenja (vidjeti dio 4.4).
• lactic acidosis (excess lactic acid in the blood). 
površine tijela (toksična epidermalna nekroliza) • laktacidoza (nakupljanje mliječne kiseline u krvi).
Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. 
Ispitivanja u bolesnika s oštećenjem bubrežne funkcije pokazuju da poremećaj funkcije bubrega utječe na eliminaciju lamivudina.
Population PK analyses using pooled pharmacokinetic data from Phase IIb and Phase III adult trials revealed no clinically relevant effect of gender on the exposure of dolutegravir. 
Populacijska farmakokinetička analiza objedinjenih farmakokinetičkih podataka iz ispitivanja faze IIb i faze III u odraslih bolesnika nije ukazala na klinički značajan učinak spola na izloženost dolutegraviru.